Listed

Champions Oncology, Inc.

CSBRNasdaqCIK 771856HealthcareFiscal year ends Apr 30

Latest reported revenue, Q1 FY2027$15.2mRevenue, Q1 FY2027, three months to 2026-07-31$15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figureThree months to Jul 31, 2026, from the 10-Q filed Sep 11, 2026.

Latest quarter: Q1 FY2027

Three months to Jul 31, 2026, against the same quarter a year earlier.

  • Revenue$15.2mRevenue, Q1 FY2027, three months to 2026-07-31$15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure+8.8% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−2.7%Operating margin, Q1 FY2027, three months to 2026-07-31. operating income / revenueOperating income: −$409.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Revenue: $15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure+1.1 pts on a year earlier
  • Net margin−2.8%Net margin, Q1 FY2027, three months to 2026-07-31. net income / revenueNet income: −$426.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Revenue: $15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure+0.5 pts on a year earlier
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flow−$547.0kFree cash flow, Q1 FY2027, three months to 2026-07-31. operating cash flow − capital expenditureOperating cash flow: −$492.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Capital expenditure: $55.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figureSign changed from a year earlier

Last eight quarters

Full statements
Revenue$15.2mOperating margin −2.7%
Diluted EPS−$0.02, Q3 FY2026
Free cash flow−$547.0k, Q1 FY2027
Champions Oncology, Inc., key figures for the last eight quarters
Line itemUnitQ2 FY20252024-10-31Q3 FY20252025-01-31Q4 FY20252025-04-30Q1 FY20262025-07-31Q2 FY20262025-10-31Q3 FY20262026-01-31Q4 FY20262026-04-30Q1 FY20272026-07-31Shape over the periods
Revenue$m13.5Revenue, Q2 FY2025, three months to 2024-10-31$13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Report this figure17.0Revenue, Q3 FY2025, three months to 2025-01-31$17.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Report this figure12.4Revenue, Q4 FY2025, three months to 2025-04-30$12.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Report this figure14.0Revenue, Q1 FY2026, three months to 2025-07-31$14.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure15.0Revenue, Q2 FY2026, three months to 2025-10-31$15.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Report this figure16.6Revenue, Q3 FY2026, three months to 2026-01-31$16.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Report this figure13.8Revenue, Q4 FY2026, three months to 2026-04-30$13.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Report this figure15.2Revenue, Q1 FY2027, three months to 2026-07-31$15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%5.4%Operating margin, Q2 FY2025, three months to 2024-10-31. operating income / revenueOperating income: $732.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Revenue: $13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Report this figure26.4%Operating margin, Q3 FY2025, three months to 2025-01-31. operating income / revenueOperating income: $4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Revenue: $17.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Report this figure(16.2%)Operating margin, Q4 FY2025, three months to 2025-04-30. operating income / revenueOperating income: −$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Revenue: $12.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Report this figure(3.8%)Operating margin, Q1 FY2026, three months to 2025-07-31. operating income / revenueOperating income: −$527.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Revenue: $14.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure1.2%Operating margin, Q2 FY2026, three months to 2025-10-31. operating income / revenueOperating income: $185.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Revenue: $15.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Report this figure(1.7%)Operating margin, Q3 FY2026, three months to 2026-01-31. operating income / revenueOperating income: −$276.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Revenue: $16.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Report this figure(3.8%)Operating margin, Q4 FY2026, three months to 2026-04-30. operating income / revenueOperating income: −$522.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Revenue: $13.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Report this figure(2.7%)Operating margin, Q1 FY2027, three months to 2026-07-31. operating income / revenueOperating income: −$409.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Revenue: $15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure
Net margin%5.4%Net margin, Q2 FY2025, three months to 2024-10-31. net income / revenueNet income: $728.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Revenue: $13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Report this figure26.4%Net margin, Q3 FY2025, three months to 2025-01-31. net income / revenueNet income: $4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Revenue: $17.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Report this figure(14.9%)Net margin, Q4 FY2025, three months to 2025-04-30. net income / revenueNet income: −$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Revenue: $12.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Report this figure(3.3%)Net margin, Q1 FY2026, three months to 2025-07-31. net income / revenueNet income: −$466.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Revenue: $14.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure1.8%Net margin, Q2 FY2026, three months to 2025-10-31. net income / revenueNet income: $268.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Revenue: $15.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Report this figure(1.7%)Net margin, Q3 FY2026, three months to 2026-01-31. net income / revenueNet income: −$279.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Revenue: $16.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Report this figure(4.8%)Net margin, Q4 FY2026, three months to 2026-04-30. net income / revenueNet income: −$667.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Revenue: $13.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Report this figure(2.8%)Net margin, Q1 FY2027, three months to 2026-07-31. net income / revenueNet income: −$426.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Revenue: $15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure
Diluted EPS$ per share0.05Diluted EPS, Q2 FY2025, three months to 2024-10-31$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Report this figure0.31Diluted EPS, Q3 FY2025, three months to 2025-01-31$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Report this figurenot reported (Diluted EPS not reported)(0.03)Diluted EPS, Q1 FY2026, three months to 2025-07-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-09-15, accession 0000771856-25-000023.Report this figure0.02Diluted EPS, Q2 FY2026, three months to 2025-10-31$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-12-15, accession 0001628280-25-057082.Report this figure(0.02)Diluted EPS, Q3 FY2026, three months to 2026-01-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-03-12, accession 0001628280-26-017345.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(0.4)Free cash flow, Q2 FY2025, three months to 2024-10-31. operating cash flow − capital expenditureOperating cash flow: −$283.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-12-15, accession 0001628280-25-057082. Derived: 6-month figure less the 3-month figure.Capital expenditure: $94.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-12-15, accession 0001628280-25-057082. Derived: 6-month figure less the 3-month figure.Report this figure0.4Free cash flow, Q3 FY2025, three months to 2025-01-31. operating cash flow − capital expenditureOperating cash flow: $490.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-03-12, accession 0001628280-26-017345. Derived: 9-month figure less the 6-month figure.Capital expenditure: $42.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-03-12, accession 0001628280-26-017345. Derived: 9-month figure less the 6-month figure.Report this figure6.6Free cash flow, Q4 FY2025, three months to 2025-04-30. operating cash flow − capital expenditureOperating cash flow: $6.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Capital expenditure: $253.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Report this figure0.6Free cash flow, Q1 FY2026, three months to 2025-07-31. operating cash flow − capital expenditureOperating cash flow: $600.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Capital expenditure: $46.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure(2.0)Free cash flow, Q2 FY2026, three months to 2025-10-31. operating cash flow − capital expenditureOperating cash flow: −$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-12-15, accession 0001628280-25-057082. Derived: 6-month figure less the 3-month figure.Capital expenditure: $242.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-12-15, accession 0001628280-25-057082. Derived: 6-month figure less the 3-month figure.Report this figure(1.4)Free cash flow, Q3 FY2026, three months to 2026-01-31. operating cash flow − capital expenditureOperating cash flow: −$1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-03-12, accession 0001628280-26-017345. Derived: 9-month figure less the 6-month figure.Capital expenditure: $37.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-03-12, accession 0001628280-26-017345. Derived: 9-month figure less the 6-month figure.Report this figure(2.2)Free cash flow, Q4 FY2026, three months to 2026-04-30. operating cash flow − capital expenditureOperating cash flow: −$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Capital expenditure: $239.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-07-27, accession 0001628280-26-049834. Derived: 12-month figure less the 9-month figure.Report this figure(0.5)Free cash flow, Q1 FY2027, three months to 2026-07-31. operating cash flow − capital expenditureOperating cash flow: −$492.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Capital expenditure: $55.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-09-11, accession 0001628280-26-061519.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$59.4mOperating margin −1.9%
Diluted EPS−$0.08, FY2026
Free cash flow−$5.0m, FY2026
Champions Oncology, Inc., key figures for the last five fiscal years
Line itemUnitFY20222022-04-30FY20232023-04-30FY20242024-04-30FY20252025-04-30FY20262026-04-30Shape over the periods
Revenue$m49.1Revenue, FY2022, twelve months to 2022-04-30$49.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-07-24, accession 0001628280-23-025464.Report this figure53.9Revenue, FY2023, twelve months to 2023-04-30$53.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-19, accession 0001628280-24-032321.Report this figure50.2Revenue, FY2024, twelve months to 2024-04-30$50.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-07-23, accession 0001628280-25-035765.Report this figure56.9Revenue, FY2025, twelve months to 2025-04-30$56.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834.Report this figure59.4Revenue, FY2026, twelve months to 2026-04-30$59.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%1.2%Operating margin, FY2022, twelve months to 2022-04-30. operating income / revenueOperating income: $607.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-07-24, accession 0001628280-23-025464.Revenue: $49.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-07-24, accession 0001628280-23-025464.Report this figure(9.8%)Operating margin, FY2023, twelve months to 2023-04-30. operating income / revenueOperating income: −$5.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-07-19, accession 0001628280-24-032321.Revenue: $53.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-19, accession 0001628280-24-032321.Report this figure(14.7%)Operating margin, FY2024, twelve months to 2024-04-30. operating income / revenueOperating income: −$7.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-07-23, accession 0001628280-25-035765.Revenue: $50.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-07-23, accession 0001628280-25-035765.Report this figure8.0%Operating margin, FY2025, twelve months to 2025-04-30. operating income / revenueOperating income: $4.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-07-27, accession 0001628280-26-049834.Revenue: $56.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834.Report this figure(1.9%)Operating margin, FY2026, twelve months to 2026-04-30. operating income / revenueOperating income: −$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-07-27, accession 0001628280-26-049834.Revenue: $59.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834.Report this figure
Net margin%1.1%Net margin, FY2022, twelve months to 2022-04-30. net income / revenueNet income: $548.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-07-24, accession 0001628280-23-025464.Revenue: $49.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-07-24, accession 0001628280-23-025464.Report this figure(9.9%)Net margin, FY2023, twelve months to 2023-04-30. net income / revenueNet income: −$5.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-07-19, accession 0001628280-24-032321.Revenue: $53.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-07-19, accession 0001628280-24-032321.Report this figure(14.5%)Net margin, FY2024, twelve months to 2024-04-30. net income / revenueNet income: −$7.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-07-23, accession 0001628280-25-035765.Revenue: $50.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-07-23, accession 0001628280-25-035765.Report this figure8.3%Net margin, FY2025, twelve months to 2025-04-30. net income / revenueNet income: $4.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-07-27, accession 0001628280-26-049834.Revenue: $56.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834.Report this figure(2.0%)Net margin, FY2026, twelve months to 2026-04-30. net income / revenueNet income: −$1.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-07-27, accession 0001628280-26-049834.Revenue: $59.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-07-27, accession 0001628280-26-049834.Report this figure
Diluted EPS$ per share0.04Diluted EPS, FY2022, twelve months to 2022-04-30$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-07-24, accession 0001628280-23-025464.Report this figure(0.39)Diluted EPS, FY2023, twelve months to 2023-04-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-07-19, accession 0001628280-24-032321.Report this figure(0.54)Diluted EPS, FY2024, twelve months to 2024-04-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-07-23, accession 0001628280-25-035765.Report this figure0.33Diluted EPS, FY2025, twelve months to 2025-04-30$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-07-27, accession 0001628280-26-049834.Report this figure(0.08)Diluted EPS, FY2026, twelve months to 2026-04-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-07-27, accession 0001628280-26-049834.Report this figure
Free cash flow$m4.1Free cash flow, FY2022, twelve months to 2022-04-30. operating cash flow − capital expenditureOperating cash flow: $6.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-07-24, accession 0001628280-23-025464.Capital expenditure: $2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-07-24, accession 0001628280-23-025464.Report this figure1.1Free cash flow, FY2023, twelve months to 2023-04-30. operating cash flow − capital expenditureOperating cash flow: $4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-07-19, accession 0001628280-24-032321.Capital expenditure: $2.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-07-19, accession 0001628280-24-032321.Report this figure(7.0)Free cash flow, FY2024, twelve months to 2024-04-30. operating cash flow − capital expenditureOperating cash flow: −$6.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-07-23, accession 0001628280-25-035765.Capital expenditure: $836.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-07-23, accession 0001628280-25-035765.Report this figure7.0Free cash flow, FY2025, twelve months to 2025-04-30. operating cash flow − capital expenditureOperating cash flow: $7.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-07-27, accession 0001628280-26-049834.Capital expenditure: $389.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-07-27, accession 0001628280-26-049834.Report this figure(5.0)Free cash flow, FY2026, twelve months to 2026-04-30. operating cash flow − capital expenditureOperating cash flow: −$4.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-07-27, accession 0001628280-26-049834.Capital expenditure: $564.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-07-27, accession 0001628280-26-049834.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Champions Oncology, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BATTERY MANAGEMENT CORP.2026-06-30$14.9m2,421,673Unchanged
NEA Management Company, LLC2026-06-30$10.6m1,713,720Unchanged
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$1.9m301,353Added+1,833
TOCQUEVILLE ASSET MANAGEMENT L.P.2026-06-30$1.8m295,658Reduced−24,016
MORGAN STANLEY2026-06-30$1.5m235,400Reduced−6,900
BANK OF AMERICA CORP /DE/2026-06-30$1.3m214,058Added+192,225
RENAISSANCE TECHNOLOGIES LLC2026-06-30$856.5k139,039Reduced−6,500
BlackRock, Inc.2026-06-30$799.9k129,848Added+5,948
Mink Brook Asset Management LLC2026-06-30$685.8k111,338Unchanged
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$470.1k76,300Reduced−877

Recent filings

All 542 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Champions Oncology, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-1616:15 ET8-K5.07 Shareholder vote results0001628280-26-066087
2026-09-1118:51 ET10-QQuarterly reportPeriod 2026-07-310001628280-26-061519
2026-09-1020:46 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-061383
2026-08-2819:35 ETDEF 14AProxy statementPeriod 2026-08-270001628280-26-059373
2026-07-2720:45 ET10-KAnnual reportPeriod 2026-04-300001628280-26-049834
2026-07-2720:31 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-049822
2026-03-3017:16 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001628280-26-021941
2026-03-1220:56 ET10-QQuarterly reportPeriod 2026-01-310001628280-26-017345
2026-03-1220:17 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-017259
2025-12-1521:59 ET10-QQuarterly reportPeriod 2025-10-310001628280-25-057082

Latest annual report

Form 10-K for the fiscal year ended Apr 30, 2026Filed Jul 27, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
771856
Tickers
CSBR
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Apr 30
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
CHAMPIONS BIOTECHNOLOGY, INC. (to 2011-03-30); CHAMPIONS SPORTS INC (to 2007-02-16)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:24 ET. Listed shows no prices and gives no investment advice.